Carboplatin hypersensitivity in children with glial tumors: a report of two cases

Tuğçe Kazgan¹, Aysu İlhan¹, Cemile Durmaz¹, Begül Yağcı-Küpeli¹
¹Adana Numune Eğitim ve Araştırma Hastanesi Çocuk Sağlığı ve Hastalıkları Kliniği; Adana, Turkey

Abstract
Carboplatin is one of the second generation platinum compounds that produces inter- and intra-strand DNA links, inhibits DNA synthesis and causes cytotoxicity. Carboplatin hypersensitivity is a well-known entity observed especially in long term usage of the drug. Carboplatin is widely used in treatment of childhood cancer and takes place as various dosages in treatment schedules of central nervous system tumors, retinoblastoma, neuroblastoma, germ cell tumors, sarcomas in children. Carboplatin hypersensitivity (CH) is a well-known entity observed especially in long term usage of the drug. CH has been reported up to %30 in pediatric case series. CH may result in cessation of the drug. Therefore, it is important to develop strategies for desensitization in these patients in whom carboplatin is essential in treatment. Herein we report two children receiving weekly carboplatin for treatment of glial tumors who developed CH after repeated doses.

CASE 1
A-sixteen-month-old female presented with multiple cafe-au-lait spots. Physical examination findings were unremarkable except for cafe-au-lait spots. Neurofibromatosis type 1 (NF1) diagnosis was also present in her father, grandmother and aunt. Cerebral magnetic resonance imaging (MRI)
revealed multiple hamartomatous lesions and bilateral thickening of canalicul and intracranial segments of optic nerves. Visual evoked potential test showed N70 and P100 components were severely affected with normal amplitudes. Carboplatin (175 mg/m² day 1) with vincristine (1.5 mg/m² day 1) were started. During the 18th week of chemotherapy (at the end of maintenance course 1), cough was observed immediately after the starting infusion of carboplatin. Shortly after cough, maculopapular rash on the face and upper trunk and slight swelling of the lips and eyebrows were noticed. Infusion was stopped and epinephrine (0.3 mg, intramuscular) was administered. Symptoms resolved in fifteen minutes. Carboplatin was cessed after development of anaphylaxis. Orbital MRI revealed stable thickening in optic nerves and VEP showed mild improvement in N70 and P100 components. Follow-up was made by MRI in 6-months-intervals. No progression was reported neither on MRI nor with VEP during 24 months without treatment.

CASE 2

Nine-year-old female had admitted to another hospital with history of convulsions two years earlier than admission to our department. She had been operated for temporal mass detected on cranial MRI for the first time. After the operation, a residual mass was observed in the primary tumor location and second operation was performed. Low grade glioneuronal tumor was reported in histopathological examination. Fifteen months after second surgery, progression was noticed in the temporal mass. She was operated for the third time. Radiotherapy was given to tumor location. After radiotherapy, chemotherapy with carboplatin (175 mg/m² day 1) and vincristin (1.5 mg/m² day 1) were started. At the 10th month of treatment, cough, hyperemia on the face and neck and swelling on the lips an eyelid were noticed during carboplatin infusion. Epinephrine (0.3 mg, intramuscular) was administered. MRI examination revealed stable mass located in temporal region and treatment was cessed due to family’s refusal.

DISCUSSION

Hypersensitivity reactions with carboplatin is a well-known condition observed in patients with low grade glioma treated with carboplatin-based chemotherapy. However, majority of reports on this subject in English medical literature includes adults and there are a few pediatric case series. The exact underlying mechanism in the carboplatin hypersensitivity and delayed type reactions are not known. However, IgE-mediated immediate type hypersensitivity is thought to be involved. Repeated doses of the drug increases the risk of hypersensitivity with highest risk reported at 8th course of carboplatin.

Hypersensitivity symptoms include cutaneous erythema, urticaria, maculopapular rash, palmar erythema, facial flushing and swelling, itching, cough, wheezing, dyspnea, chills, rigor, throat and chest tightness, blood pressure changes. Weekly or monthly administration of the drug were found to be equally affecting hypersensitivity incidence. However, weekly administration resulted earlier hypersensitivity development. Carboplatin hypersensitivity was reported more frequently in females than males. In our patients, CH was noticed during 12th and 24th carboplatin infusions and both of our patients were females similar to findings reported in literature.

It is difficult to make a accurate decision about continuation of treatment with carboplatin in these patients who have developed mild or severe allergic reactions. It has been reported that the frequency of a more severe allergic reaction after re-exposure was 32%. Carboplatin is one of the most effective chemotherapeutic agent in treatment of low grade gliomas in children. Therefore in case of hypersensitivity reaction, a desensitization protocol is required as the replacement of the drug with another agent with same efficacy is not possible. Various desensitization protocols have been reported. Confino-Cohen et al. used different diluted concentrations of carboplatin and started with the lowest diution with premedication including antiemetic and dexamethasone. Success rate was reported to be 95% with desensitization. However, a current study reported low eficacy with desensitization protocol. Shah et al. proposed a clinical algorithm using carboplatin rechallenge with H1 and H2 antagonists, corticosteroids and prolonged infusion instead of abandoning carboplatin.

Hypersensitivity reactions are more common than it is reported. Repeated doses of carboplatin and combination with vincristin increases the risk. The possibility of hypersensitivity reactions should be
kept in mind especially in children with low grade glioma treated with this combination. Desensitization strategies can be used in case of CH in appropriate clinical conditions.

REFERENCES